Inflammation

Of 7,914 ESR results Loop ran on urban working professionals in the latest 12-month window, 22.2% sit above the gender-adjusted threshold for elevated inflammation — the rate at which red blood cells settle faster than they should because the blood is thick with the proteins an inflammatory response throws off. ESR is the oldest and bluntest inflammation test in routine use, and that bluntness is the point: it catches inflammation wherever it is coming from, without saying why. In a working population, a one-in-five elevation rate is the first sign that a meaningful share of the workforce is carrying a low-grade inflammatory burden into their most productive years.

The distribution sits mostly in the normal band, with the elevation concentrated just over the line:

This band table uses the raw cutoffs that read the same for everyone. The headline 22.2% uses the gender-adjusted clinical thresholds (>20 mm/hr for women, >15 for men), which is why the two numbers differ slightly. Most of the non-normal mass is the borderline band — the 21–40 range where the marker is raised but no acute illness is obvious. That is the band where chronic, low-grade inflammation lives.

The shape of this distribution is the first thing worth reading carefully. Acute inflammation — an active infection, a flare of an autoimmune condition — pushes ESR into the high tens and beyond. Only 4.6% of the sample sits in the elevated-or-high range above 40 mm/hr, and a fraction of those are catching a transient illness on the day of the test. The story is not in that tail. It is in the 14.6% borderline band, where the marker is persistently nudged up by a process too quiet to feel and too non-specific to name from this test alone. A working population with a fat acute tail would be a population with an outbreak. A working population with a fat borderline band is a population with a slow metabolic and nutritional drift. This is the latter.

Women show 2.6× the inflammation of men — but anemia explains most of it#

The single largest cut in the data is gender. It is also the most misread.

One in three women tested shows elevated inflammation against one in eight men. WHI 2025 reported the same 2.2× pattern and read it as a standalone finding — women carrying "almost twice the inflammatory burden of their male peers." The 2026 data lets us test what is actually driving it, because the same reports carry haemoglobin.

The answer is anemia. ESR is mechanically inflated by low haemoglobin: when red cells are sparse, they sink faster regardless of whether any inflammation is present. Among the women in this sample with both markers, the elevation rate splits cleanly on iron status.

An anemic woman is 2.2× more likely to register elevated ESR than a woman with normal iron — and India's working women are anemic at rates the Anemia page puts above 40%. A large part of the female "inflammation" signal is the iron-deficiency signal wearing a different lab coat. The two findings are not independent; they are partly the same women, counted twice.

Inflammation and blood sugar travel together#

The more durable finding sits at the intersection of inflammation and metabolism. Among reports carrying both an ESR and an HbA1c, the ESR-elevated group is markedly more likely to be in glucose dysfunction.

Nearly half the inflamed group shows abnormal glucose against roughly a third of the non-inflamed group. To rule out the anemia confound — which raises ESR in women without involving metabolism — the same cut restricted to men, who are rarely anemic, holds the pattern almost exactly: 51.3% glucose dysfunction in ESR-elevated men against 34.3% in ESR-normal men. The link survives where the artefact can't reach it.

The clinical literature has named this overlap for two decades: low-grade inflammation is one of the components of metabolic syndrome, alongside central obesity, dyslipidaemia, hypertension, and impaired fasting glucose (Hotamisligil, Nature, 2006). The Loop data is a population-scale echo of that mechanism — the people whose blood is quietly inflamed are disproportionately the people whose blood sugar is quietly drifting, the same 38.7% glucose-dysfunction band the Blood Sugar page maps in full.

One negative result is worth recording alongside the positive one. Triglycerides — the lipid most tightly coupled to insulin resistance — did not separate on ESR status: 32.6% of the ESR-elevated group sat above 150 mg/dL against 32.9% of the ESR-normal group, a non-difference. That the glucose link is strong while the triglyceride link is flat suggests ESR is tracking the inflammatory-glycaemic axis specifically rather than dyslipidaemia broadly. It also disciplines the claim. ESR is not a general metabolic alarm that lights up for every cardiometabolic risk at once; in this dataset it co-travels with glucose and not with lipids, which is the more defensible and more useful version of the finding.

The inflammatory load roughly doubles after 50#

Inflammation climbs with age, but the slope is gentler than the glucose curve and the break comes later.

The 20s through 40s sit in a tight band between 17% and 22%. The jump comes after 50, where the rate leaps to 36.2% and then to 43.1% past 60. This is the pattern clinicians call inflammaging — the slow, age-linked rise in baseline inflammation as immune regulation loosens and accumulated metabolic and cellular stress shows up in the blood (Franceschi & Campisi, J Gerontol, 2014); the Age & Generation page reads this late-life climb against the markers that break early, and the contrast is the point. For an employer, the read is the inverse of the glucose page: inflammation is one risk marker that does not yet show heavy early-career deterioration in this workforce. The load is concentrated in the older bands — which, on the dependent layer, means parents.

The contrast with blood sugar is the useful part. Glucose dysfunction in this same workforce doubles between the 20s and the 30s — the metabolic curve breaks in early career. Inflammation does not. It holds flat through the decades when work intensifies most and bends only in the post-50 window, which on a typical corporate policy is overwhelmingly the parent and parent-in-law layer rather than the employee. The two markers age differently because they are reading different stages of the same disease: early glucose drift is the metabolic process announcing itself, while the late inflammatory climb is the cumulative damage that drift leaves behind. An employee can be metabolically compromised for a decade before their inflammation markers catch up.

The gender gap is widest in early career and narrows with age#

Splitting gender by age shows the female elevation is not uniform across life — it is most extreme young, then converges.

In the 20s, women are elevated at 3.4× the male rate. The gap is largest exactly where iron-deficiency anemia is most prevalent — the menstruating, often under-screened younger female cohort — which is consistent with the anemia confound carrying the early-career female signal. From the 50s, as women's anemia eases post-menopause and men's age-linked inflammation climbs, the two curves move toward each other. By 60, both sexes are elevated at comparable rates. The "women are more inflamed" story is really a "young women are iron-deficient" story laid over a shared late-life inflammaging curve.

Delhi NCR leads the metros, and Delhi women run at one in two#

Mapping each report's pincode to a metro bucket covers the great majority of the sample and ranks the cities cleanly.

Delhi NCR carries the highest inflammatory burden of the five metros, at nearly double Pune's rate. The city-by-gender cut sharpens it: 45.9% of Delhi women tested show elevated ESR, against 18.4% of Delhi men. Delhi's pairing of the worst metro inflammation rate with the report's well-documented Delhi liver-dysfunction and air-quality findings is consistent with the literature linking chronic PM2.5 exposure to systemic inflammation (Brook et al., Circulation, 2010) — though ESR is too non-specific to attribute the city gap to pollution alone, and the female share again points back toward anemia as a large component.

The city-by-age cut adds one more note. Delhi's inflammation concentrates in the older bands — 51.9% elevated in the 50s and 55.1% past 60, the steepest late-life climb of any metro — while Bengaluru and Pune stay comparatively flat into the older ages. The metros do not just differ in level; they differ in how fast inflammation accumulates across a working life.

Dependents carry nearly twice the inflammation of employees#

The dependent-layer pattern that runs through every biomarker in this report holds for inflammation too.

Dependents — the spouses, parents, and parents-in-law on the employer's policy — show roughly double the elevation rate of employees. Part of the gap is age, since the dependent pool skews older and inflammation climbs late. Part is sex, since the dependent pool skews female and the female rate is higher. And part, once again, is anemia in the older female dependents who sit at the intersection of both.

The relationship-by-gender split makes the concentration explicit.

Male dependents are elevated at 23.7% against 10.1% for male employees — more than double, the age effect showing through cleanly because anemia barely touches men. Female dependents reach 37.0%, the single highest of the four cells. The dependent layer is where the inflammation, the anemia, and the late-life metabolic load all concentrate at once — and it is the layer least likely to ever see a blood panel. The employee gets the annual checkup, the company webinar, the on-site screening drive. The covered parent gets none of it, and carries the heaviest inflammatory burden of anyone on the policy.